Compare SLP & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLP | PROF |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.6M | 238.1M |
| IPO Year | 1996 | 2017 |
| Metric | SLP | PROF |
|---|---|---|
| Price | $14.80 | $6.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $24.00 | $12.00 |
| AVG Volume (30 Days) | ★ 371.2K | 83.4K |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | 0.26 | ★ 1.41 |
| Revenue | ★ $59,577,000.00 | $16,098,000.00 |
| Revenue This Year | $3.80 | $92.40 |
| Revenue Next Year | $5.90 | $64.10 |
| P/E Ratio | $54.23 | ★ $4.83 |
| Revenue Growth | 10.52 | ★ 50.73 |
| 52 Week Low | $11.09 | $3.92 |
| 52 Week High | $34.01 | $8.95 |
| Indicator | SLP | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 56.97 |
| Support Level | $14.18 | $5.75 |
| Resistance Level | $15.37 | $7.07 |
| Average True Range (ATR) | 0.72 | 0.40 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 67.16 | 74.07 |
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.